Press Releases Regencell Bioscience Holdings Limited

Equities

RGC

KYG7487R1002

Delayed Nasdaq Other stock markets 16:30:00 2024-05-09 EDT			5-day change	1st Jan Change
5.56 ^USD	-10.61%		-14.33%	-47.05%

2023	Regencell Bioscience Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2023	CI
2023	Regencell Bioscience Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2022	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Regencell Bioscience : Resignation of Yi-Chung Chao as Director - Form 6-K	01-02	PU
Regencell Bioscience : Form of Letter of Lock-up Undertaking - Form 6-K	12-15	PU
Regencell Bioscience : Announces First Half 2023 Management Financial Results - Form 6-K	23-06-15	PU
Regencell Bioscience : Changes in Registrant’s Certifying Accountant - Form 6-K	23-03-17	PU
Regencell Bioscience : Appointment of Chief Business Officer - Form 6-K	23-02-28	PU
Regencell Bioscience : Letter of Lock-Up Undertaking - Form 6-K	23-01-04	PU
Regencell Bioscience : Resignation of Chief Medical Officer - Form 6-K	22-12-22	PU
Regencell Bioscience’s Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial	22-09-12	BU
Regencell Bioscience : Announces First Half 2022 Management Financial Results - Form 6-K	22-06-02	PU
Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period	22-05-18	BU
Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO	22-05-16	BU
Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO	22-05-16	BU
Regencell Bioscience’s Investigational Liquid-Formula RGC-COV19TM Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Efficacy Trial	22-02-16	BU
Regencell Bioscience : Investigational Liquid-Formula RGC-COV19TM Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Efficacy Trial - Form 6-K	22-02-16	PU
Regencell Bioscience : Appoints Dr. William Wing-Yan Lo, JP to its Board of Directors - Form 6-K	21-12-13	PU
Regencell Bioscience Holdings Limited Appoints Dr. William Wing-Yan Lo, JP to its Board of Directors	21-12-13	BU
Regencell Bioscience Holdings Limited Announces Over $1 Million Ordinary Share Purchase by CEO	21-11-22	BU
Regencell Bioscience Holdings Limited Included in the MSCI World Micro Cap Index	21-11-22	BU
Regencell Bioscience : JOINT VENTURE AGREEMENT (Form 6-K)	21-09-07	PU
Regencell Bioscience Holdings Limited : Establishes a Joint Venture to Offer COVID Treatment	21-09-02	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Regencell Bioscience Holdings Limited

Equities

RGC

KYG7487R1002

Press Releases

Filters